Funded Startups in Schlieren
Across these 20 recent rounds in Schlieren, the largest disclosed amount is ImmunOs Therapeutics’s $11M (Series C, 2024-09-17).
Across these 20 recent rounds in Schlieren, the largest disclosed amount is ImmunOs Therapeutics’s $11M (Series C, 2024-09-17). That figure sits above most other disclosed rounds in the list, while the next-highest disclosed amounts are $21M (Pexapark, 2023-09-26) and $25M (Memo Therapeutics, Series B, 2022-02-16), which indicates a skew toward a small number of materially larger financings rather than a uniform distribution. Payout sizes also show clear lower-end clustering: several rounds are under $1M disclosed, including SalesPlaybook at $660K (Seed, 2022-09-14) and Topadur Pharma at $620K (Grant, 2022-06-07), alongside multiple undisclosed amounts (e.g., HeiQ Materials on 2023-07-06).
Most rounds are concentrated in specific sectors and time windows. Biotechnology appears in 8 of the 20 entries (e.g., arcoris bio $8M on 2025-11-03; LimmaTech Biologics $7M on 2025-02-17; Kuros Biosciences $6M on 2022-09-15), while Energy and Financial Services each show up 2 times. Temporally, entries span from 2021-06-09 (VirtaMed, $600K) through 2025-11-16 (Forgis, $5M), with multiple cluster points in 2023 (notably 2023-07-06 and 2023-09 around numarics $11M and Pexapark $21M). Geographic references remain consistently Schlieren, with “Schlieren, Zurich, Switzerland” used for many biotechnology and healthcare entries rather than alternate city names.
Most recent rounds
20 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this Schlieren set, and how do they compare to the rest of the disclosed amounts?
The largest disclosed round is Memo Therapeutics at $25M (Series B, 2022-02-16). Next-largest disclosed amounts are $21M for Pexapark (Series C, 2023-09-26) and $11M for ImmunOs Therapeutics (Series C, 2024-09-17), while many other disclosed rounds cluster well below $10M (for example, SalesPlaybook $660K on 2022-09-14 and Topadur Pharma $620K on 2022-06-07).
How much of the list uses undisclosed or unknown amounts, and what does that imply when comparing round sizes?
Three of the 20 rows show “undisclosed” amounts: HeiQ Materials on 2023-07-06, Fixposition on 2022-12-21, and Avelo on 2022-12-12. Because they are excluded from disclosed comparisons, any “largest” or “smallest” conclusions should rely on the 17 rows with stated amounts.
Where are the biggest time clusters in the 20 most recent rows?
There are noticeable multi-entry clusters in 2023 and in mid-2022. In 2023, two rounds share 2023-07-06 (HeiQ Materials “undisclosed” and numarics at $11M), and Pexapark closes $21M on 2023-09-26; in 2022, Memo Therapeutics closes on 2022-02-16 ($25M) and multiple entries cluster later in the year (SalesPlaybook $660K on 2022-09-14 and Kuros Biosciences $6M on 2022-09-15).
Which sectors are over-represented in these Schlieren entries?
Biotechnology is the dominant sector by count, appearing in 8 of the 20 rows (e.g., arcoris bio $8M on 2025-11-03; LimmaTech Biologics $7M on 2025-02-17; ImmunOs Therapeutics $11M on 2024-09-17; Kuros Biosciences $6M on 2022-09-15). Energy appears twice (8links $3M on 2024-05-13; Pexapark $21M on 2023-09-26), and Financial Services appears twice (numarics $11M on 2023-07-06; TONI Digital $13M on 2023-01-10).
Are there stage patterns or stage gaps that stand out across the disclosed rounds?
Seed and “Series Unknown” are both common categories among the 20 entries: for example, numarics raises Seed $11M on 2023-07-06, SalesPlaybook raises Seed $660K on 2022-09-14, and multiple companies are labeled “Series Unknown” (e.g., Pregnolia $3M on 2023-11-16 and HeiQ Materials on 2023-07-06 with an undisclosed amount). At the high end, disclosed large financings cluster in later-stage labels such as Series C (Pexapark $21M on 2023-09-26; ImmunOs Therapeutics $11M on 2024-09-17) and Series B (TONI Digital $13M on 2023-01-10; Memo Therapeutics $25M on 2022-02-16).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.